SCHEDULE: Deep Track Capital Discloses 8.33% Stake in X4 Pharmaceuticals

Deep Track Capital, along with affiliated entities, has reported beneficial ownership of 8.33% of X4 Pharmaceuticals' common stock as of June 30, 2026.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., David Kroin, and Deep Track Special Opportunities Fund, LP have collectively disclosed beneficial ownership of 8,040,894 shares of X4 Pharmaceuticals, Inc. common stock.
• This represents 8.33% of the class of securities outstanding as of June 30, 2026.
• The filing indicates that David Kroin may be considered a control person for Deep Track Capital, LP.
• The reported shares include 2,162,137 Pre-Funded Warrants, which are subject to a 9.99% maximum exercise limitation.
• The total number of outstanding common shares used for calculation was 96,481,833 as of May 1, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating significant institutional ownership and potential strategic interest, but without immediate performance-driven catalysts.

Positives

• Significant institutional ownership by Deep Track Capital and its affiliates, suggesting confidence in X4 Pharmaceuticals' long-term prospects.
• The disclosure of Pre-Funded Warrants indicates a potential for increased ownership, subject to limitations.
• The filing is a Schedule 13G, typically filed by passive investors, suggesting the current stake is not for the purpose of changing control.

Negatives

• The 9.99% maximum exercise limitation on Pre-Funded Warrants caps immediate potential ownership increase.
• The filing does not provide any new operational or financial performance data for X4 Pharmaceuticals.

Risks

• The exercise of Pre-Funded Warrants is subject to a 9.99% ownership cap, which could limit the reporting persons' ability to increase their stake beyond this threshold.
• Potential for future changes in investment strategy by Deep Track Capital, which could impact X4 Pharmaceuticals' stock.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from X4 Pharmaceuticals. It primarily reports on current beneficial ownership as of June 30, 2026.

Industry Context

StockSavvy.ai notes that significant stake disclosures by institutional investors like Deep Track Capital are common in the biotechnology sector, often reflecting strategic investment decisions based on pipeline developments or market opportunities. This filing places X4 Pharmaceuticals within the focus of active institutional capital.

Stakeholder Impact

• Shareholders: Increased institutional ownership may signal confidence, potentially influencing stock price, but the passive nature of the filing suggests no immediate control change intent.
• Management: The significant stake held by Deep Track Capital may lead to increased engagement or dialogue with the company's board and management.
• Potential Investors: The disclosure provides transparency on a major shareholder, aiding in investment analysis.

Next Steps

• Monitoring any future filings from Deep Track Capital regarding their stake in X4 Pharmaceuticals.
• Observing X4 Pharmaceuticals' operational and clinical developments that may influence institutional investor sentiment.

Key Dates

Keywords

X4 Pharmaceuticals, Schedule 13G, Deep Track Capital, Beneficial Ownership, Pre-Funded Warrants, Institutional Investor, Biotechnology